Renaissance Technologies LLC decreased its holdings in shares of Climb Bio, Inc. (NASDAQ:CLYM - Free Report) by 32.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 217,300 shares of the company's stock after selling 103,300 shares during the quarter. Renaissance Technologies LLC owned about 0.38% of Climb Bio worth $1,489,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. AQR Capital Management LLC purchased a new position in shares of Climb Bio during the 1st quarter worth $27,000. Goldman Sachs Group Inc. acquired a new position in Climb Bio in the first quarter valued at about $147,000. Marshall Wace LLP acquired a new position in Climb Bio in the second quarter valued at about $46,000. Qube Research & Technologies Ltd purchased a new position in Climb Bio during the second quarter worth about $43,000. Finally, Jane Street Group LLC purchased a new position in Climb Bio during the second quarter worth about $184,000. Hedge funds and other institutional investors own 69.76% of the company's stock.
Climb Bio Stock Up 3.9%
Climb Bio stock opened at $14.39 on Thursday. The firm has a market cap of $826.56 million, a PE ratio of -17.34 and a beta of 0.08. Climb Bio, Inc. has a 52-week low of $1.54 and a 52-week high of $14.55. The company's 50 day moving average is $12.53 and its two-hundred day moving average is $9.53.
Climb Bio (NASDAQ:CLYM - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.03. On average, equities research analysts anticipate that Climb Bio, Inc. will post -0.84 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on CLYM shares. Wall Street Zen upgraded shares of Climb Bio from a "sell" rating to a "hold" rating in a report on Saturday, May 9th. Guggenheim assumed coverage on shares of Climb Bio in a report on Monday, June 8th. They issued a "buy" rating and a $35.00 target price for the company. Royal Bank Of Canada began coverage on Climb Bio in a research report on Monday, August 3rd. They issued an "outperform" rating and a $23.00 target price on the stock. Wedbush upped their price target on Climb Bio from $17.00 to $20.00 and gave the stock an "outperform" rating in a research note on Monday, July 27th. Finally, Truist Financial raised their price target on Climb Bio from $17.00 to $25.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $22.75.
View Our Latest Stock Analysis on Climb Bio
Climb Bio Profile
(
Free Report)
Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company's mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.
At the heart of Climb Bio's approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.
Read More
Want to see what other hedge funds are holding CLYM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Climb Bio, Inc. (NASDAQ:CLYM - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Climb Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Climb Bio wasn't on the list.
While Climb Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
